WillItSurvive
No grouping · United States

Akston Biosciences Corporation

Veterinary biotech making long-acting antibody drugs for dogs, IPO stalled since October 2025.

Losing its protection
Assessed 29 July 2026 · Evidence as of 29 July 2026
The structural protection is eroding.
On the recordSince 29 July 2026 · Checkable from January 1, 2027 · Every call on the record Checkpoint: Shreveport, Louisiana manufacturing facility targeted commercial occupancy
The call

Akston has real lab assets and a 2027 approval target for dog cancer treatment, but its IPO has sat unpriced for nine months with conflicting financials.

Akston makes long-acting biologics (protein treatments) for dogs and cats. The company owns two manufacturing plants and has partnerships with Purdue and Cornell, but the big animal health companies like Zoetis and Elanco already sell similar drugs to veterinarians and can copy Akston's approach without permission. Akston's lead drug may get approved in 2027, but the company has not sold any approved product yet, the IPO has stalled for nine months with conflicting financial numbers in different documents, and cash will run short if the IPO does not close soon at a decent price.

Why
01
AI pressure: None apparent. No AI product targets canine biologics directly; bigger risk is rivals using AI-driven discovery to speed up competing antibody programs. Could AI do the core job? Unlikely.
02
Bigger players: Zoetis, Elanco, Boehringer Ingelheim. These firms already sell canine biologics like Cytopoint and Librela and could copy Akston's Fc-fusion approach with far more cash and vet reach. Could a giant copy it? Yes, easily.
03
What protects it. Two GMP manufacturing sites, 29 patents, and existing Purdue/Cornell trial data give Akston a head start rivals would need years to match.
What would change this call
Akston's IPO prices or is withdrawn/further delayed within 90 days of July 29, 2026. Shows whether investors believe the $8-$10 range and 2027 plan are credible.
USDA issues or denies conditional approval for AKS-701d in 2027. Confirms whether Akston's core regulatory moat claim actually converts to a product.
Zoetis, Elanco, or Boehringer announce a competing long-acting Fc-fusion pet therapeutic. Would show incumbents closing the gap before Akston can commercialize.
Key numbers
  • IPO targets $20M at $8-$10 per share (2025-10-08)
  • TTM revenue $0.17M vs $28.6M net loss (2025-12-30)
  • Total funding raised about $36.9M to date (2025-10-07)
Named risks
  • IPO may never price or price far below $8 to $10 range, cutting off capital needed for 2027 approval. Severity: high
  • Financial figures conflict sharply across S-1 amendments, unreconciled as of April 2026. Severity: high
  • No approved products yet, lead candidate AKS-701d depends on unguaranteed 2027 USDA conditional approval. Severity: high
  • Large incumbents like Zoetis and Boehringer face no structural barrier to copying Ambifect Fc-fusion technology. Severity: medium
  • Small $20 million deal size with single small-cap underwriter ThinkEquity vulnerable to market sentiment shifts. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Zoetislosing toCytopoint and Librela already commercial and dominant in atopic dermatitis and OA pain as of 2026, Akston has no approved product
Boehringer Ingelheimlosing toNamed PitchBook competitor with existing vet distribution and R&D scale vs Akston's pre-revenue pipeline
Dechra PharmaceuticalscontestingBought Akston's insulin programs in July 2024, now a named competitor in broader vet biologics
Elancolosing toAlready ships commercial anti-NGF biologics for pain, ahead of Akston's AKS-548d still in pipeline as of 2026
LoyalcontestingVC-backed canine longevity biotech named as direct competitor by PitchBook in 2026 profile
Questions people ask
Is Akston Biosciences profitable in 2026?
No. Financial figures conflict across S-1 amendments, with a later snapshot showing trailing-12-month revenue of just $0.17 million against a $28.6 million net loss as of December 30, 2025, indicating the company is not currently profitable.
Has Akston Biosciences IPO priced yet?
No. As of July 29, 2026, Akston's S-1 remains unpriced with a $0 market cap and no trading history, despite five amendments filed between November 2025 and April 2026 for its proposed AXTN listing.
What is Akston Biosciences' lead product?
AKS-701d, an anti-PD-L1 antibody for canine bladder cancer, is Akston's lead candidate, in clinical trials at Purdue and Cornell veterinary schools, targeting USDA conditional approval around 2027 as announced October 29, 2025.
Who are Akston Biosciences' biggest competitors?
Zoetis dominates adjacent indications with Cytopoint for canine atopic dermatitis and Librela for osteoarthritis pain, while PitchBook names Dechra Pharmaceuticals, Boehringer Ingelheim Animal Health, Vetmab Bio, Saiba Animal Health, and Loyal as direct competitors as of 2026.
Does Akston Biosciences have any approved products?
No. As of July 2026, Akston has no approved commercial biologics; its pipeline candidates including AKS-701d, AKS-699, and AKS-548d remain in clinical trials or preclinical stages, with the earliest conditional USDA licensure targeted for 2027.
How much did Akston Biosciences raise in its IPO?
Akston filed to raise up to approximately $20 million by selling about 2.22 million shares at $8 to $10 each, with ThinkEquity as sole bookrunner, per its October 8, 2025 S-1 filing, though the deal had not priced as of July 2026.
Timeline
  • 2026-06-01AKS-699 reports one-year pruritus control comparable to lokivetmab in head-to-head study
  • 2026-04-10Fifth S-1 amendment filed, IPO still unpriced
  • 2026-02-27Akston opens $7 million, 31,000-sq-ft manufacturing facility in Shreveport, Louisiana
  • 2025-11-01Akston initiates once-weekly GLP-1 feline obesity clinical trial
  • 2025-10-29Akston announces clinical trial launch for AKS-701d canine bladder cancer therapy
  • 2025-10-08Akston files S-1 for IPO, proposed ticker AXTN, targeting up to $20 million raise
  • 2024-10-31Purdue University and Akston begin bladder cancer immunotherapy trial for dogs
  • 2024-07Akston sells veterinary insulin programs to Dechra Limited
Revision history
29 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
American Airlines GroupSafe Superintelligence Inc.Wayfair
More companies losing its protection →
Sources